The negative effect of impaired LASP1 levels on patient outcome is supported by the case of a 66‐year‐old woman diagnosed to suffer from CML in chronic phase in 2011. This evidence concerns the gene LASP1 and chronic myelogenous leukemia, BCR-ABL1 positive.